Thornburg Investment Management Inc. Has $2.46 Million Position in BioMarin Pharmaceutical Inc. $BMRN

Thornburg Investment Management Inc. boosted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 305.9% in the second quarter, Holdings Channel.com reports. The fund owned 43,061 shares of the biotechnology company’s stock after buying an additional 32,453 shares during the quarter. Thornburg Investment Management Inc.’s holdings in BioMarin Pharmaceutical were worth $2,464,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in BMRN. Activest Wealth Management bought a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth $26,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $39,000. CIBC Private Wealth Group LLC increased its stake in shares of BioMarin Pharmaceutical by 38.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 179 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter valued at approximately $40,000. Finally, Parallel Advisors LLC raised its position in shares of BioMarin Pharmaceutical by 62.2% in the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 295 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN opened at $64.67 on Friday. The firm has a market cap of $12.52 billion, a P/E ratio of 174.78, a PEG ratio of 0.46 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm’s 50 day moving average price is $61.70 and its two-hundred day moving average price is $58.15.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. During the same period last year, the business posted $1.44 earnings per share. The firm’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, analysts forecast that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BMRN has been the topic of several recent analyst reports. Barclays lifted their price objective on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. HC Wainwright cut their target price on shares of BioMarin Pharmaceutical from $60.00 to $59.00 and set a “neutral” rating on the stock in a report on Tuesday, August 18th. Canaccord Genuity Group lifted their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Morgan Stanley boosted their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Weiss Ratings cut shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $88.79.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.